Overcoming acquired resistance to AZD9291, a third generation EGFR inhibitor, through modulation of MEK/ERK-dependent Bim and Mcl-1 degradation

PURPOSE: The mechanisms accounting for anticancer activity of AZD9291 (osimertinib or TAGRISSO™), an approved third generation EGFR inhibitor, in EGFR-mutant non-small cell lung cancer (NSCLC) cells and particularly for the subsequent development of acquired resistance are unclear and thus are the f...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Clin Cancer Res
Main Authors: Shi, Puyu, Oh, You-Take, Deng, Liang, Zhang, Guojing, Qian, Guoqing, Zhang, Shuo, Ren, Hui, Wu, Grant, Legendre, Benjamin, Anderson, Emily, Ramalingam, Suresh S., Owonikoko, Taofeek K., Chen, Mingwei, Sun, Shi-Yong
פורמט: Artigo
שפה:Inglês
יצא לאור: 2017
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5668147/
https://ncbi.nlm.nih.gov/pubmed/28765329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-1574
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים